search
Back to results

Lateral Branch Cooled Radiofrequency Denervation vs. Conservative Therapy for Sacroiliac Joint Pain

Primary Purpose

Sacroiliac Joint Pain

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SInergy Cooled Radiofrequency
Medical Management
Sponsored by
Avanos Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sacroiliac Joint Pain focused on measuring Back Pain, Low Back Pain, Sacroiliac Back Pain

Eligibility Criteria

21 Years - 110 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age greater than or equal to 21 years.
  2. Able to understand the informed consent, and able to complete outcome measures.
  3. Sacroiliac joint (SIJ) pain that is refractory to standard of care treatments such as non-steroidal anti-inflammatory drugs (NSAIDS), physical therapy, etc.
  4. At least one positive SIJ pain provocation test (Distraction, Gaenslen's, FABER, Sacral Sulcus tenderness, thigh thrust, compression or sacral thrust).
  5. Back pain is predominantly below the lumbar (L) 5 vertebrae.
  6. Chronic low back pain lasting for longer than three months.
  7. Greater than 50% pain relief lasting for the expected duration of anesthetic or medication from a therapeutic or diagnostic SIJ injection.
  8. Greater than 50% pain relief lasting the duration of anesthetic from lateral branch block (done on different days than SIJ injection).
  9. Stabilized on pain medication regimen for > 2 months, as defined by a < 10% change in dosage.
  10. Numeric rating scale indicating an average pain score of > 4 over the last seven days. (returned to pre-lateral branch block baseline pain).
  11. All other possible sources of low back pain have been ruled out as the primary pain generator, including, but not limited to: suspected advanced degenerative joint disease, the intervertebral discs, bone fracture, the zygapophyseal joints, the hip joint, symptomatic spondylolisthesis, tumor, and other regional soft tissue structures (this is done by physical exam, medical history, and magnetic resonance imaging/computed tomography/X-ray, as required).
  12. Willing to utilize double barrier contraceptive method, if of child-bearing potential.
  13. Willingness to provide informed consent and to comply with the requirements of this protocol for the full duration of the study.
  14. Physician believes ablation of the SIJ is an appropriate treatment for the patient.

Exclusion Criteria:

  1. Poorly controlled severe psychiatric illness or ongoing psychological barriers to recovery, as determined by the treating physician.
  2. Spinal pathology that may impede recovery such as spina bifida occulta, grade II or higher spondylolisthesis at vertebrae L5/sacroiliac (S) 1, or scoliosis.
  3. Symptomatic moderate or severe foraminal or central canal stenosis.
  4. Systemic infection or localized infection at anticipated introducer entry site.
  5. Uncontrolled immunosuppression (e.g., acquired immune deficiency syndrome (AIDS), cancer, diabetes, etc.)
  6. Chronic severe conditions such as rheumatoid/inflammatory arthritis.
  7. Pregnancy or recent delivery (within three months).
  8. Active radiculopathy pain from lumbar spine.
  9. Active hip pathology.
  10. Major surgery within three months prior to signing informed consent.
  11. Prior radiofrequency denervation of the lateral sacral nerves.
  12. Ongoing/unresolved worker's compensation, injury litigation, military medical board, or disability remuneration claims.
  13. Allergy to injected substances or medications used in procedure.
  14. Body mass index (BMI) > 40 kilograms/meter (squared).
  15. Current prescribed opioid medications equivalent to 90 mg of morphine per 24 hours or greater.
  16. Subject is currently implanted with pacemaker, stimulator, or defibrillator.
  17. Participation in another clinical trial/investigation that could interfere with this trial 30 days prior to signing informed consent.
  18. Subject is unwilling or unable to comply with the protocol requirements.

Sites / Locations

  • Mehul Desai
  • Millennium Pain Center
  • Ochsner Medical Center
  • Shravani Durbhakula
  • Walter Reed National Military Medical Center
  • Brigham and Women's Hospital
  • Premier Pain Centers
  • Adam Carinci
  • Womack Army Medical Center
  • The Center for Clinical Research
  • Wake Forest Baptist Health
  • Clinical Investigations
  • Oregon Health and Science University
  • Lynn Kohan
  • Michael DePalma

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

SInergy Cooled Radiofrequency

Medical Management

Arm Description

Halyard Health SInergy Cooled Radiofrequency in addition to standard medical management

Standard Medical Management

Outcomes

Primary Outcome Measures

Change in average daily pain Numeric Rating Scale (NRS) score
Numeric Rating Scale (NRS) - score range = 0 - 10. "0" corresponds to "no pain" and "10" indicates "worst pain imaginable". The means of these scores and their respective standard deviations are reported for each study group.

Secondary Outcome Measures

The proportion of subjects with at least a 2 points decrease or 30% drop in average daily pain related NRS score AND a rating of at least 5 on the Patient Global Impression of Change (PGIC)
Numeric Rating Scale (NRS) - score range = 0 - 10. "0" corresponds to "no pain" and "10" indicates "worst pain imaginable". The means of these scores and their respective standard deviations are reported for each study group. PGIC - score range = 1 - 7. "1" corresponds to "very much improved" and "7" indicates "very much worse" pertaining to overall activity, symptoms, emotions, and quality of life. The means of these scores and their respective standard deviations are reported for each study group.
Mean change in score of Patient Global Impression of Change (PGIC)
PGIC - score range = 1 - 7. "1" corresponds to "very much improved" and "7" indicates "very much worse" pertaining to overall activity, symptoms, emotions, and quality of life. The means of these scores and their respective standard deviations are reported for each study group.
Mean change in score of Short Form 36-Physical Functioning (SF36-PF)
Short Form 36-PF - score range = 0 - 100. "0" corresponds to "greatest disability" and "100" indicates "no disability". The means of these scores and their respective standard deviations are reported for each study group.
Mean change in score of Oswestry Disability Index (ODI)
ODI - score range = 0 - 100. "0" corresponds to "no disability" and "100" indicates the "maximum disability possible". The means of these scores and their respective standard deviations are reported for each study group.
Mean change in score of EuroQuol (EQ) 5D-5L
This tool involves two components: 1) descriptive system - five questions that are scored 1-5, each with "1" indicating no problems and "5" indicating the worst problem related to the question, and 2) EQ-Visual Analog Scale (VAS) - score range = 0 - 100. "0" corresponds to the "worst imaginable health state" and "100" indicates the "best imaginable health state". The means of these scores and their respective standard deviations are reported for each study group.

Full Information

First Posted
July 18, 2018
Last Updated
March 21, 2023
Sponsor
Avanos Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT03601949
Brief Title
Lateral Branch Cooled Radiofrequency Denervation vs. Conservative Therapy for Sacroiliac Joint Pain
Official Title
A Prospective, Multi-center, Randomized, Assessor Blind, Controlled Study Comparing Lateral Branch Cooled Radiofrequency Denervation to Conservative Therapy as Treatment for Sacroiliac Joint Pain in a Military and Civilian Population
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
June 29, 2018 (Actual)
Primary Completion Date
August 9, 2021 (Actual)
Study Completion Date
June 23, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Avanos Medical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, randomized, controlled, multi-center clinical study. Approximately 208 subjects will be enrolled at approximately 12-15 active duty military, veterans' care, and civilian sites. Eligible subjects will be randomized in 1:1 ratio to receive either Sacroiliac denervation using CRF (treatment group) or standard medical management ("SMM," control group).
Detailed Description
This study will be a 12-month prospective, randomized, controlled, prospective, open-label, multi-center clinical study. Adult subjects over the age of 21 with diagnosed chronic intractable sacroiliac joint pain (≥ 3 months), who have been previously unresponsive to conservative therapy and who meet the selection criteria are eligible to participate in this study. Approximately 208 subjects will be enrolled at up to 15 sites in a 1:1 randomization ratio to receive either denervation using the SInergy System (cooled radiofrequency (CRF), treatment group) or standard medical management (SMM, control group). Follow-up will be conducted for a total of 12 months post-Coolief (cooled radiofrequency ablation) procedure, with the primary endpoint being completed at month 3. The control arm will utilize physician prescribed standard medical management (SMM). For this protocol, this includes, but is not limited to, medications, physical therapy, lifestyle changes, acupuncture, yoga, chiropractic, and therapeutic injections. An optional crossover-to-treatment design was adopted for subjects randomized to standard medical management after their 3-month visit, because it would be considered unethical to withhold treatment that could potentially offer pain relief to those subjects undergoing standard medical management who continue to suffer from pain. Eligibility includes BOTH of the following: 50% pain relief lasting for the expected duration of anesthetic or medication from a therapeutic or diagnostic sacroiliac joint injection; AND 50% pain relief lasting for the expected duration of anesthetic from a standardized set of lateral branch blocks, with total volume of no more than 1 milliliter (ml) of 0.5% Bupivacaine, Ropivacaine (or similar). Ideally, 0.5 ml will be utilized at L5 and the remaining 0.5 ml should be divided in at least two locations along the foramen line After the CRF treatment, the CRF treatment group subjects will visit the blinded assessor for follow up at 1, 3, 6, 9, and 12 months. At the month 3 visit (three months post-randomization), subjects initially randomized to the conservative therapy group will be assessed to determine eligibility to receive CRF treatment. If the conservative treatment subjects fail conservative therapy at 3 months (defined as failure to obtain a 2-point decrease in average pain score from baseline AND failure to obtain a rating of at least 5 on the Patient Global Impression of Change (PGIC) scale), they will be given the option of receiving CRF treatment. Subjects who choose to cross-over will ideally receive treatment within 30 days of their 3-month visit but they must receive treatment within 90 days of their 3-month visit. They will then be followed-up at 1, 3, 6, 9, and 12 months following CRF denervation (new Day 0). If the conservative treatment group subjects refuse or don't qualify for CRF treatment at 3 months, they will subsequently be followed-up at 6, 9, and 12 months from their Day 0. Primary Analysis is planned after all initially treated subjects have completed their 3-month post-procedure visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sacroiliac Joint Pain
Keywords
Back Pain, Low Back Pain, Sacroiliac Back Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
The study is an assessor blinded trial and deliberate action will be needed to ensure the blind remains. This begins with randomization procedures and carries through the follow up visits. It is suggested that all follow up visit documentation not contain the visit number, but instead utilize visit dates to track progress.
Allocation
Randomized
Enrollment
210 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SInergy Cooled Radiofrequency
Arm Type
Experimental
Arm Description
Halyard Health SInergy Cooled Radiofrequency in addition to standard medical management
Arm Title
Medical Management
Arm Type
Active Comparator
Arm Description
Standard Medical Management
Intervention Type
Device
Intervention Name(s)
SInergy Cooled Radiofrequency
Other Intervention Name(s)
SInergy
Intervention Description
ablation of low back pain
Intervention Type
Other
Intervention Name(s)
Medical Management
Other Intervention Name(s)
Standard Medical Management
Intervention Description
physical therapy, medications, lifestyle changes
Primary Outcome Measure Information:
Title
Change in average daily pain Numeric Rating Scale (NRS) score
Description
Numeric Rating Scale (NRS) - score range = 0 - 10. "0" corresponds to "no pain" and "10" indicates "worst pain imaginable". The means of these scores and their respective standard deviations are reported for each study group.
Time Frame
Baseline and 3 months
Secondary Outcome Measure Information:
Title
The proportion of subjects with at least a 2 points decrease or 30% drop in average daily pain related NRS score AND a rating of at least 5 on the Patient Global Impression of Change (PGIC)
Description
Numeric Rating Scale (NRS) - score range = 0 - 10. "0" corresponds to "no pain" and "10" indicates "worst pain imaginable". The means of these scores and their respective standard deviations are reported for each study group. PGIC - score range = 1 - 7. "1" corresponds to "very much improved" and "7" indicates "very much worse" pertaining to overall activity, symptoms, emotions, and quality of life. The means of these scores and their respective standard deviations are reported for each study group.
Time Frame
Baseline and 3 months
Title
Mean change in score of Patient Global Impression of Change (PGIC)
Description
PGIC - score range = 1 - 7. "1" corresponds to "very much improved" and "7" indicates "very much worse" pertaining to overall activity, symptoms, emotions, and quality of life. The means of these scores and their respective standard deviations are reported for each study group.
Time Frame
Baseline and 3 months
Title
Mean change in score of Short Form 36-Physical Functioning (SF36-PF)
Description
Short Form 36-PF - score range = 0 - 100. "0" corresponds to "greatest disability" and "100" indicates "no disability". The means of these scores and their respective standard deviations are reported for each study group.
Time Frame
Baseline and 3 months
Title
Mean change in score of Oswestry Disability Index (ODI)
Description
ODI - score range = 0 - 100. "0" corresponds to "no disability" and "100" indicates the "maximum disability possible". The means of these scores and their respective standard deviations are reported for each study group.
Time Frame
Baseline and 3 months
Title
Mean change in score of EuroQuol (EQ) 5D-5L
Description
This tool involves two components: 1) descriptive system - five questions that are scored 1-5, each with "1" indicating no problems and "5" indicating the worst problem related to the question, and 2) EQ-Visual Analog Scale (VAS) - score range = 0 - 100. "0" corresponds to the "worst imaginable health state" and "100" indicates the "best imaginable health state". The means of these scores and their respective standard deviations are reported for each study group.
Time Frame
Baseline and 3 months
Other Pre-specified Outcome Measures:
Title
The mean change in pain-related medication
Description
The absolute mean difference between analgesic use at baseline and that at 3 months post-randomization.
Time Frame
Baseline and 3 months
Title
Healthcare Utilization Questionnaire
Description
Used to evaluate the use or need for other healthcare treatments (e.g., physical therapy, visit(s) to chiropractor). The evaluation is not based on a point-based scale, but rather is based on responses made by trial subjects to the questions, with the determination made by the investigator.
Time Frame
Baseline and 3 months
Title
Time from treatment to return to work/duty
Description
Trial subject will be asked if/when she/he returned to work/duty
Time Frame
3 months post-intervention
Title
Time from treatment to return of pain date
Description
Trial subject will be asked if/when she/he experienced a return of pain
Time Frame
3 months post-intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
110 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age greater than or equal to 21 years. Able to understand the informed consent, and able to complete outcome measures. Sacroiliac joint (SIJ) pain that is refractory to standard of care treatments such as non-steroidal anti-inflammatory drugs (NSAIDS), physical therapy, etc. At least one positive SIJ pain provocation test (Distraction, Gaenslen's, FABER, Sacral Sulcus tenderness, thigh thrust, compression or sacral thrust). Back pain is predominantly below the lumbar (L) 5 vertebrae. Chronic low back pain lasting for longer than three months. Greater than 50% pain relief lasting for the expected duration of anesthetic or medication from a therapeutic or diagnostic SIJ injection. Greater than 50% pain relief lasting the duration of anesthetic from lateral branch block (done on different days than SIJ injection). Stabilized on pain medication regimen for > 2 months, as defined by a < 10% change in dosage. Numeric rating scale indicating an average pain score of > 4 over the last seven days. (returned to pre-lateral branch block baseline pain). All other possible sources of low back pain have been ruled out as the primary pain generator, including, but not limited to: suspected advanced degenerative joint disease, the intervertebral discs, bone fracture, the zygapophyseal joints, the hip joint, symptomatic spondylolisthesis, tumor, and other regional soft tissue structures (this is done by physical exam, medical history, and magnetic resonance imaging/computed tomography/X-ray, as required). Willing to utilize double barrier contraceptive method, if of child-bearing potential. Willingness to provide informed consent and to comply with the requirements of this protocol for the full duration of the study. Physician believes ablation of the SIJ is an appropriate treatment for the patient. Exclusion Criteria: Poorly controlled severe psychiatric illness or ongoing psychological barriers to recovery, as determined by the treating physician. Spinal pathology that may impede recovery such as spina bifida occulta, grade II or higher spondylolisthesis at vertebrae L5/sacroiliac (S) 1, or scoliosis. Symptomatic moderate or severe foraminal or central canal stenosis. Systemic infection or localized infection at anticipated introducer entry site. Uncontrolled immunosuppression (e.g., acquired immune deficiency syndrome (AIDS), cancer, diabetes, etc.) Chronic severe conditions such as rheumatoid/inflammatory arthritis. Pregnancy or recent delivery (within three months). Active radiculopathy pain from lumbar spine. Active hip pathology. Major surgery within three months prior to signing informed consent. Prior radiofrequency denervation of the lateral sacral nerves. Ongoing/unresolved worker's compensation, injury litigation, military medical board, or disability remuneration claims. Allergy to injected substances or medications used in procedure. Body mass index (BMI) > 40 kilograms/meter (squared). Current prescribed opioid medications equivalent to 90 mg of morphine per 24 hours or greater. Subject is currently implanted with pacemaker, stimulator, or defibrillator. Participation in another clinical trial/investigation that could interfere with this trial 30 days prior to signing informed consent. Subject is unwilling or unable to comply with the protocol requirements.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Curd, MS
Organizational Affiliation
Avanos Medical
Official's Role
Study Director
Facility Information:
Facility Name
Mehul Desai
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20037
Country
United States
Facility Name
Millennium Pain Center
City
Bloomington
State/Province
Illinois
ZIP/Postal Code
61704
Country
United States
Facility Name
Ochsner Medical Center
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70115
Country
United States
Facility Name
Shravani Durbhakula
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Facility Name
Walter Reed National Military Medical Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20889
Country
United States
Facility Name
Brigham and Women's Hospital
City
Chestnut Hill
State/Province
Massachusetts
ZIP/Postal Code
02467
Country
United States
Facility Name
Premier Pain Centers
City
Shrewsbury
State/Province
New Jersey
ZIP/Postal Code
07702
Country
United States
Facility Name
Adam Carinci
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Womack Army Medical Center
City
Fort Bragg
State/Province
North Carolina
ZIP/Postal Code
28307
Country
United States
Facility Name
The Center for Clinical Research
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Wake Forest Baptist Health
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
Clinical Investigations
City
Edmond
State/Province
Oklahoma
ZIP/Postal Code
73013
Country
United States
Facility Name
Oregon Health and Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Lynn Kohan
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Facility Name
Michael DePalma
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23235
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Lateral Branch Cooled Radiofrequency Denervation vs. Conservative Therapy for Sacroiliac Joint Pain

We'll reach out to this number within 24 hrs